Celyad Oncology Sa Stock Performance
| CLYYF Stock | USD 0.15 0.00 0.00% |
The firm shows a Beta (market volatility) of -0.2, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Celyad Oncology are expected to decrease at a much lower rate. During the bear market, Celyad Oncology is likely to outperform the market. At this point, Celyad Oncology SA has a negative expected return of -0.42%. Please make sure to confirm Celyad Oncology's standard deviation and skewness , to decide if Celyad Oncology SA performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Celyad Oncology SA has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in March 2026. The current disturbance may also be a sign of long-run up-swing for the company stockholders. ...more
| Begin Period Cash Flow | 17.2 M | |
| Total Cashflows From Investing Activities | -126 K |
Celyad |
Celyad Oncology Relative Risk vs. Return Landscape
If you would invest 20.00 in Celyad Oncology SA on November 11, 2025 and sell it today you would lose (5.00) from holding Celyad Oncology SA or give up 25.0% of portfolio value over 90 days. Celyad Oncology SA is currently producing negative expected returns and takes up 2.4125% volatility of returns over 90 trading days. Put another way, 21% of traded pink sheets are less volatile than Celyad, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Celyad Oncology Target Price Odds to finish over Current Price
The tendency of Celyad Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.15 | 90 days | 0.15 | about 84.5 |
Based on a normal probability distribution, the odds of Celyad Oncology to move above the current price in 90 days from now is about 84.5 (This Celyad Oncology SA probability density function shows the probability of Celyad Pink Sheet to fall within a particular range of prices over 90 days) .
Celyad Oncology Price Density |
| Price |
Predictive Modules for Celyad Oncology
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Celyad Oncology SA. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Celyad Oncology's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Celyad Oncology Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Celyad Oncology is not an exception. The market had few large corrections towards the Celyad Oncology's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Celyad Oncology SA, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Celyad Oncology within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.4 | |
β | Beta against Dow Jones | -0.2 | |
σ | Overall volatility | 0.02 | |
Ir | Information ratio | -0.21 |
Celyad Oncology Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Celyad Oncology for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Celyad Oncology SA can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Celyad Oncology SA generated a negative expected return over the last 90 days | |
| Celyad Oncology SA has some characteristics of a very speculative penny stock | |
| Celyad Oncology SA has high likelihood to experience some financial distress in the next 2 years | |
| Celyad Oncology SA has accumulated 2.87 M in total debt with debt to equity ratio (D/E) of 0.15, which may suggest the company is not taking enough advantage from borrowing. Celyad Oncology SA has a current ratio of 0.95, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Celyad Oncology until it has trouble settling it off, either with new capital or with free cash flow. So, Celyad Oncology's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Celyad Oncology SA sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Celyad to invest in growth at high rates of return. When we think about Celyad Oncology's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (26.51 M) with profit before overhead, payroll, taxes, and interest of 5 K. | |
| Celyad Oncology SA has accumulated about 6.1 M in cash with (26.64 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.39, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
Celyad Oncology Fundamentals Growth
Celyad Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Celyad Oncology, and Celyad Oncology fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Celyad Pink Sheet performance.
| Return On Equity | -0.93 | |||
| Return On Asset | -0.29 | |||
| Current Valuation | 11.81 M | |||
| Shares Outstanding | 22.59 M | |||
| Price To Book | 5.05 X | |||
| Price To Sales | 24,222 X | |||
| EBITDA | (24.73 M) | |||
| Cash And Equivalents | 6.1 M | |||
| Cash Per Share | 0.39 X | |||
| Total Debt | 2.87 M | |||
| Debt To Equity | 0.15 % | |||
| Book Value Per Share | 1.36 X | |||
| Cash Flow From Operations | (26.64 M) | |||
| Earnings Per Share | (1.51) X | |||
| Total Asset | 79.94 M | |||
About Celyad Oncology Performance
By analyzing Celyad Oncology's fundamental ratios, stakeholders can gain valuable insights into Celyad Oncology's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Celyad Oncology has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Celyad Oncology has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor-T cell-based therapies for the treatment of cancer. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium. Celyad Oncology operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 87 people.Things to note about Celyad Oncology SA performance evaluation
Checking the ongoing alerts about Celyad Oncology for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Celyad Oncology SA help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Celyad Oncology SA generated a negative expected return over the last 90 days | |
| Celyad Oncology SA has some characteristics of a very speculative penny stock | |
| Celyad Oncology SA has high likelihood to experience some financial distress in the next 2 years | |
| Celyad Oncology SA has accumulated 2.87 M in total debt with debt to equity ratio (D/E) of 0.15, which may suggest the company is not taking enough advantage from borrowing. Celyad Oncology SA has a current ratio of 0.95, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Celyad Oncology until it has trouble settling it off, either with new capital or with free cash flow. So, Celyad Oncology's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Celyad Oncology SA sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Celyad to invest in growth at high rates of return. When we think about Celyad Oncology's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (26.51 M) with profit before overhead, payroll, taxes, and interest of 5 K. | |
| Celyad Oncology SA has accumulated about 6.1 M in cash with (26.64 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.39, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Celyad Oncology's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Celyad Oncology's stock is overvalued or undervalued compared to its peers.
- Examining Celyad Oncology's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Celyad Oncology's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Celyad Oncology's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Celyad Oncology's pink sheet. These opinions can provide insight into Celyad Oncology's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Celyad Pink Sheet analysis
When running Celyad Oncology's price analysis, check to measure Celyad Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celyad Oncology is operating at the current time. Most of Celyad Oncology's value examination focuses on studying past and present price action to predict the probability of Celyad Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celyad Oncology's price. Additionally, you may evaluate how the addition of Celyad Oncology to your portfolios can decrease your overall portfolio volatility.
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |